TRCT
GLUE icon

Tower Research Capital (TRC)’s Monte Rosa Therapeutics GLUE Stock Holding History

Tower Research Capital (TRC)’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.2K Buy
3,722
+3,036
+443% +$58.1K ﹤0.01% 2573
2025
Q4 		$10.8K Sell
686
-2,757
-80% -$37.2K ﹤0.01% 3709
2025
Q3 		$25.5K Sell
3,443
-1,549
-31% -$8.2K ﹤0.01% 3085
2025
Q2 		$22.5K Buy
4,992
+2,149
+76% +$9.59K ﹤0.01% 3611
2025
Q1 		$13.2K Sell
2,843
-2,600
-48% -$15.9K ﹤0.01% 3392
2024
Q4 		$37.8K Buy
5,443
+3,584
+193% +$26.9K ﹤0.01% 2737
2024
Q3 		$9.85K Sell
1,859
-11,593
-86% -$58.5K ﹤0.01% 3826
2024
Q2 		$50.3K Buy
13,452
+12,930
+2,477% +$65.9K ﹤0.01% 3097
2024
Q1 		$3.68K Sell
522
-7,274
-93% -$43.1K ﹤0.01% 4819
2023
Q4 		$44K Sell
7,796
-9,367
-55% -$36.7K ﹤0.01% 3216
2023
Q3 		$82.2K Buy
17,163
+15,495
+929% +$99.8K ﹤0.01% 2128
2023
Q2 		$11.4K Sell
1,668
-676
-29% -$4.37K ﹤0.01% 3978
2023
Q1 		$18K Buy
2,344
+888
+61% +$6.17K ﹤0.01% 3557
2022
Q4 		$11K Sell
1,456
-13,364
-90% -$111K ﹤0.01% 3818
2022
Q3 		$121K Buy
14,820
+7,575
+105% +$69.6K ﹤0.01% 2402
2022
Q2 		$70K Buy
7,245
+4,630
+177% +$46.5K ﹤0.01% 2580
2022
Q1 		$37K Buy
2,615
+2,157
+471% +$29.9K ﹤0.01% 2962
2021
Q4 		$9K Sell
458
-927
-67% -$19.4K ﹤0.01% 4692
2021
Q3 		$31K Buy
1,385
+985
+246% +$28.2K ﹤0.01% 3349
2021
Q2 		$9K Buy
+400
New +$8.15K ﹤0.01% 4434

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Tower Research Capital (TRC)'s GLUE Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Monte Rosa Therapeutics (GLUE) stake by 443% in Q1 2026, buying an estimated $58.1K and bringing the position to 3,722 shares worth $61.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2573.

Tower Research Capital (TRC) first reported a position in GLUE in Q2 2021 and has held it in 20 quarters since. The position peaked at $121K in Q3 2022. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Tower Research Capital (TRC) held 3,722 shares of Monte Rosa Therapeutics worth $61.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 3,036 Monte Rosa Therapeutics shares in Q1 2026, an estimated $58.1K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2573 holding.
  • Tower Research Capital (TRC) first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Monte Rosa Therapeutics position peaked at $121K in Q3 2022.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.